Skip to content
Open access

Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.

Aug 2026 · Cancer Treatment and Research Communications · Vol 49, pp. 101411 · 0 citations · 22 references
Medicine

TL;DR

The hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC is suggested, although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival.

Abstract

Purpose

Even though thyroid transcription factor-1 (TTF-1)-negative non-squamous non-small cell lung cancer (NSCLC) is associated with a poor prognosis, the optimal treatment regimens have not been established. We conducted this multicenter retrospective study to evaluate the association between specific treatment choices and survival outcomes in this population.

Methods

We retrospectively analyzed data from patients with TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitors plus chemotherapy between 2019 and 2022. TTF-1 expression levels were assessed by immunohistochemistry performed in routine clinical practice at each participating institution. Patients with EGFR or ALK driver alterations were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated to compare treatment options, focusing particularly on the use of CTLA-4 antibodies.

Results

A total of 58 patients were included in the analysis. Univariate analysis revealed no association between PFS and treatment options, including CTLA-4 antibodies, pemetrexed, and vascular endothelial growth factor (VEGF) inhibitors. Conversely, OS was longer in patients treated with CTLA-4 antibody regimens (p = 0.045, log-rank test). Multivariate analysis showed a hazard ratio of 0.36 (95% confidence interval: 0.12-1.07) for OS in patients receiving CTLA-4 antibody regimens compared with those who did not.

Conclusion

Although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival, it did suggest the hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC.

Read PDF

Similar papers

Open access Sep 2026

Greater survival benefits in small cell lung cancer patients: a real-world study with immune checkpoint inhibitors therapy

Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.

Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al. · 0 citations
Open access Sep 2026

Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study.

BACKGROUND For advanced lung cancer patients, an increasing number of long responders to Immune Checkpoint Inhibitors (ICI) is observed. Thus, the optimal treatment duration remains unclear whereas indefinite treatment is associated to immune-related adverse events (irAEs) and financial burden. OBJECTIVE To describe...

Arnaud De Gunten, A. Mogenet, A. Bronstein et al. · 0 citations
Open access Sep 2026

Initiation of immune checkpoint inhibitor therapy in winter is associated with improved overall survival in patients with advanced non-small cell lung cancer

Immune checkpoint inhibitors (ICIs), targeting programmed cell death protein 1, programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4, have become a standard treatment resulting in improved outcomes in advanced non-small cell lung cancer (NSCLC); however, the influence of seasonal variations on trea...

Zhang-Xuan Chen, Jing-Si Chen, Yang Yao et al. · 0 citations
Open access Oct 2026

Real-World Evaluation of the Immune Checkpoint Inhibitor Score (IChIS) in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Higher IChIS was independently associated with shorter PFS in patients with advanced NSCLC receiving ICIs, supporting its potential role as a simple and readily available prognostic biomarker.

Ismail Dilli, E. E. Kavak, M. Atak et al. · 0 citations
Open access Sep 2026

Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?

Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...

A. Agbarya, N. S. Shrem, Asmah Miari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.